Bimatoprost ocular with preservative
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Eye drops containing bimatoprost with preservative.
Treatment of elevated intraocular pressure in chronic open-angle glaucoma
Treatment of elevated intraocular pressure in ocular hypertension
As monotherapy or as adjunctive therapy to beta-blockers in the treatment of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults.
Instil one drop into the affected eye(s) once daily in the evening.
Do not exceed the once daily dose, as more frequent use may lessen the intraocular pressure lowering effect.
Children under 18 years
Precautions and Warnings
Predisposition to hypotension
Predisposition to iritis
Predisposition to low heart rate
Predisposition to uveitis
Risk factors for cystoid macular oedema
Wearing of contact lenses
Chronic obstructive pulmonary disease
History of viral ocular infection
Moderate hepatic impairment
Pseudophakia with torn posterior lens capsule
Advise patient blurred vision may affect ability to drive/operate machinery
Contains benzalkonium chloride
Advise patient hair growth may occur on areas of skin repeatedly exposed
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Advise patient that some eye changes may be permanent
Contains phosphate: Risk of calcification in existing notable cornea damage
Advise patient to avoid touching the eye/other surfaces with container tip
Before initiating treatment inform patient of possibility of eyelash growth
Before initiating treatment inform patient of risk of eyelid skin darkening
Before starting treatment inform patient of risk of increased iris pigment
Remove contact lenses before use and re-insert 15 minutes after use
Before treatment begins, advise patients there is a risk of prostaglandin analogue periorbitopathy (PAP). Some changes may be permanent and lead to an impaired field of vision. In cases where only one eye is treated there might be differences in appearance between eyes.
Pregnancy and Lactation
Use bimatoprost with caution during pregnancy.
The manufacturer notes that bimatoprost eye drops should only be used in pregnancy if necessary. There is limited data for the use of bimatoprost in pregnant women and it is unknown if bimatoprost crosses the human placenta. Animal studies indicate a low risk.
Bimatoprost is contraindicated during breastfeeding.
The manufacturer notes that the decision must be taken to cease breastfeeding or to discontinue the medication. There is limited data for the use of bimatoprost eye drops during human breastfeeding. The molecular weight (around 416) and moderate plasma protein binding (around 88%) indicates that it will be excreted into breast milk, yet the very low blood concentration and short elimination half life indicates that notable exposure will not occur.
Abnormal liver function tests
Blurred vision (transient)
Cystoid macular oedema
Exacerbation of obstructive pulmonary disease
Exacerbation of pre-existing asthma
Hair growth abnormal
Hyperpigmentation of skin
Increased iris pigmentation
Lid margin crusting
Periorbital skin pigmentation
Reduced visual acuity
Sensation of foreign body in eye
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: June 2022
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.
Summary of Product Characteristics: Bimatoprost 0.1mg/ml eye drops, solution. Aspire Pharma Ltd. Revised May 2022.
Summary of Product Characteristics: Bimatoprost 0.3mg/ml eye drops, solution. Aspire Pharma Ltd. Revised May 2022.
Summary of Product Characteristics: Lumigan 0.1mg/ml eye drops, solution. AbbVie Ltd. Revised April 2022.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 17 June 2022
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.